Researchers at The University of Texas MD Anderson Cancer Center have identified how ATRX gene mutations fundamentally reprogram the epigenome in glioma, providing a potential roadmap for targeted cancer therapies. By altering the three-dimensional structure of chromatin, these mutations activate specific developmental gene pathways—such as WNT5A, SLITRK6, and the HOXA family—that drive tumor growth and cell migration, according to a study co-led by Dr. Jason Huse and Dr. Kunal Rai.
How ATRX mutations drive glioma progression
ATRX mutations are a defining genetic feature in many gliomas, yet their specific role in tumor behavior remained unclear until recent findings. According to Dr. Jason Huse, professor of Anatomic Pathology at MD Anderson, the loss of ATRX does not cause random cellular damage. Instead, it systematically reorganizes chromatin—the complex of DNA, RNA, and proteins that forms chromosomes—to rewrite the cell’s regulatory architecture.
This structural remodeling creates new interactions within the genome. These interactions switch on developmental gene programs that the tumor exploits to facilitate its own growth and spread. Researchers identified several key pathways activated by this process, including:
- WNT5A: Linked to neurogenesis and the movement of cancer cells.
- SLITRK6: Associated with malignant brain tumors and cell migration.
- HOXA gene family: Regulators of early brain development.
Chromatin is not just a storage unit for DNA; its 3D folding pattern acts as a control switch for gene expression. When ATRX is lost, that “switch” is flipped, allowing cancer cells to hijack developmental pathways to survive.
Can targeting HOXA pathways slow tumor growth?
The research team, which included Dr. Prit Benny Malgulwar, Dr. Anand Singh, and Dr. Ajay Saw, investigated whether blocking these newly activated pathways could inhibit tumor progression. Laboratory experiments demonstrated that interfering with WNT5A or SLITRK6 successfully reduced cancer cell movement in vitro.
The most interesting results came from targeting the HOXA pathway. Using a peptide called HXR9 to disrupt HOXA-mediated signaling, researchers observed that the treatment triggered cancer cell death, slowed tumor growth and extended survival in preclinical models. According to Dr. Kunal Rai, professor of Genomic Medicine, these findings highlight the necessity of examining the functional consequences of mutations rather than focusing solely on the genetic sequence itself.
What are the implications for other cancer types?
While this study focused on glioma, the implications may extend to other malignancies. ATRX mutations are present in several cancer types beyond the brain. Dr. Rai noted that the discovery of epigenetic dysfunction and cellular plasticity could provide a broader framework for understanding how mutations drive cancer across different tissues.
Currently, treatment options for many aggressive gliomas remain limited. The identification of these biomarkers and drug targets offers a new direction for personalized medicine. By integrating genetic, epigenetic, and structural data, clinicians may eventually be able to match the right patient with the right treatment at the right time.
Frequently Asked Questions
What is the ATRX gene?
ATRX is a gene that plays a critical role in maintaining the structure of chromatin. Mutations in this gene are common in various gliomas and are known to drive tumor progression.
How does HXR9 work?
HXR9 is a peptide used in research to disrupt HOXA-mediated signaling. In preclinical studies, it has been shown to trigger cancer cell death, slow the growth of ATRX-deficient tumors and extend survival.
Are these treatments available for patients today?
No. While these findings are promising, further clinical research will be needed before the findings can be translated into patient care.
Are you interested in the latest developments in cancer research? Subscribe to our newsletter for updates on emerging therapies and genomic medicine.
